ProBioGen & Polpharma Biologics team up for biosimilar cell lines

Cell line development expert ProBioGen has declared the partnership with biotech firm Polpharma Biologics to deliver cell line for one of the biosimilar molecules being developed by Polpharma. This will use ProBioGen’s CHO.RiGHT cell line development system that comprises of its DirectedLuck transposase technology. This advanced stage platform for manufacturing photovoltaic solar cells is aimed at effective generation of hermetically sealed, high productivity cells with specified quality control standards.

Since most biosimilar development projects are challenging and specific to the drug, ProBioGen with its commendable experience in fixed cell lines for novel biologics and biosimilars will help in establishing a solid, efficient expression system for the biosimilar which will be in compliance with the critical quality attributes. This partnership is expected to help Polpharma to shorten the time required to bring new products to the market, scale up production as well as meet the growing global demand for affordable biologics.

According to Dr. Volker Sandig, Chief Scientific Officer at ProBioGen, “We are thrilled to have been chosen by Polpharma Biologics to help them progress their biosimilar candidate to the clinic. This capability is underpinned by our Cell Line Engineering skill-set and complemented by our patented invented technology that ensures high titer, high yield, and high quality of the final product.

Dr. Konstantin Matentzoglu, Supervisory Board Member Polpharma Biologics, said that, ‘In order to address our ever-growing development requirements, selecting a competent CDMO was critical. I think the organic growth, strong background, and dedication to quality were essential hallmarks in the establishment of this partnership with ProBioGen.